THIS WEEK
The most anticipated metabolic liver disease trial of 2026 is approaching its readout window, and most people covering the GLP-1 space have not explained why survodutide is a different compound from tirzepatide in the ways that actually matter. We break down the Phase 2 MASH data, the mechanism behind the glucagon receptor advantage for liver disease, and why the second receptor choice in a dual agonist changes the entire clinical profile. On the regulatory front, Issue 2 covered seven peptides moving toward FDA advisory panel review in July. The April 15 announcement actually covered twelve. We cover the five that were missed and update the complete picture.
The GLP-1/Glucagon Dual Agonist Built Specifically for Fatty Liver Disease
Survodutide — Boehringer Ingelheim and Zealand Pharma — Phase 3 SYNCHRONIZE and LIVERAGE Programs
Survodutide is a once-weekly subcutaneous dual agonist that activates the GLP-1 receptor and the glucagon receptor. That second receptor is not GIP, which is what tirzepatide uses. The distinction sounds technical but it has real clinical consequences, particularly for patients with fatty liver disease, and it is the reason survodutide has a development story that is genuinely differentiated from every other compound in the metabolic space right now.
The Phase 2 obesity data is strong. In the primary obesity trial, survodutide produced 18.7% weight loss at 46 weeks in completers, with 40% of participants achieving 20% or greater weight loss. The weight loss curve had not plateaued at trial end, suggesting the full efficacy potential had not been reached at 46 weeks. That is a meaningful signal in a class where plateau effects tend to appear clearly within the trial window.
The more distinctive data is in MASH. Metabolic dysfunction-associated steatohepatitis is a progressive liver disease caused by fat accumulation and inflammatory damage to hepatocytes. It affects an estimated 6 to 8% of the global adult population and has no approved pharmacotherapy beyond the recently approved resmetirom. In survodutide's Phase 2 MASH trial, 83% of participants achieved histological liver improvement at 48 weeks, with 62% achieving MASH resolution. These are large effect sizes for a disease that is notoriously difficult to treat and where histological endpoints require liver biopsy to confirm.
The glucagon receptor component is the mechanistic reason for this liver-specific profile. Glucagon receptor activation directly stimulates hepatic fatty acid oxidation and reduces liver fat accumulation through pathways that GLP-1 and GIP receptor agonism do not reach with the same potency. The liver is the primary site of glucagon receptor expression. When you activate GLP-1 and glucagon together, you get appetite suppression and reduced caloric intake via GLP-1, plus direct hepatic fat oxidation via glucagon. Tirzepatide's GIP component drives its own advantages, particularly in insulin sensitization, but the hepatic fat oxidation mechanism is not its primary strength.
The Phase 3 program is the SYNCHRONIZE program for obesity (SYNCHRONIZE-1 and SYNCHRONIZE-2, which enrolled 1,481 total participants) and the LIVERAGE program for MASH. Last participant visits for SYNCHRONIZE-1 and SYNCHRONIZE-2 are expected in the first half of 2026, with analyzed results anticipated later in 2026. The FDA has granted survodutide Breakthrough Therapy designation for MASH and Fast Track designation for NASH, along with EMA PRIME scheme acceptance.
The bottom line: survodutide is not another tirzepatide competitor in a crowded field. It is the compound most likely to establish a standard of care in MASH, which currently has almost none. The obesity data is strong enough to be competitive but the liver data is where the real differentiation lives.
Full premium section continues with a detailed comparison of survodutide vs tirzepatide efficacy data, the SYNCHRONIZE-2 baseline characteristics published in Diabetes, Obesity and Metabolism in February 2026, and the LIVERAGE MASH program timeline.
Survodutide vs Tirzepatide: The Efficacy Comparison
Tirzepatide SURMOUNT-1 showed 22.5% mean weight loss at 72 weeks at the highest dose (15 mg). Survodutide Phase 2 showed 18.7% at 46 weeks in completers, with the curve still rising. These are not directly comparable because the trials are different lengths and used different patient populations, but the directional picture is that survodutide's obesity efficacy is competitive with tirzepatide at doses tested so far, and the Phase 3 program is designed to test higher doses.
The more meaningful comparison is in MASH. Tirzepatide's SURMOUNT-NASH trial showed 51% MASH resolution at 52 weeks in a Phase 2 trial. Survodutide's Phase 2 MASH trial showed 62% resolution at 48 weeks. These are again non-comparable across trials, but the glucagon receptor mechanism in survodutide provides a distinct and potentially complementary pathway to the GLP-1-mediated effects that tirzepatide relies on.
SYNCHRONIZE-2 Baseline Characteristics
The February 2026 publication in Diabetes, Obesity and Metabolism describes the SYNCHRONIZE-2 baseline cohort: 752 participants, mean age 55.7 years, mean BMI 36.5 kg/m2, mean body weight 104.1 kg, mean HbA1c 7.4%. Participants were randomized 1:1:1 to survodutide 3.6 mg, survodutide 6.0 mg, or placebo with modified diet and physical activity recommendations. The 76-week primary endpoints are percentage change in body weight and achievement of 5% or greater body weight reduction from baseline.
The HbA1c of 7.4% at baseline is notable. This is a relatively well-controlled diabetes population, which is clinically relevant given the theoretical concern about glucagon receptor agonism driving hepatic glucose production. A more poorly controlled population would present greater risk of the glucagon component worsening glycemia. Phase 3 results will determine whether the GLP-1 offset is sufficient across the full range of baseline glycemic control.
What Positive LIVERAGE Results Would Mean
MASH currently has one approved pharmacotherapy: resmetirom (Rezdiffra), a thyroid hormone receptor-beta agonist approved by the FDA in March 2024. Survodutide with a positive LIVERAGE readout would be the second approved treatment for MASH and the first incretin-based approach to receive approval for that indication. Given the prevalence of MASH (estimated 38 million adults in the US alone), a positive readout would represent a major commercial and clinical milestone for both Boehringer Ingelheim and the glucagon receptor agonist class.
The Second Receptor in Dual Agonist Design
The incretin drug class has produced two approved dual agonists with different second receptor choices: tirzepatide activates GLP-1 and GIP, while survodutide activates GLP-1 and glucagon. Both are dual agonists. The shared receptor is GLP-1. The distinct receptors drive fundamentally different tissue distributions and clinical profiles.
GIP Receptor Agonism: The Tirzepatide Profile
GIP receptor agonism acts primarily at the adipocyte, the beta cell, and the gut. At the adipocyte, GIP receptor activation improves insulin sensitivity and may improve fat storage dynamics. In the context of a GLP-1 agonist, GIP receptor co-activation appears to enhance the insulin-sensitizing effect and may reduce the GI side effect burden of GLP-1 agonism alone, which is part of why tirzepatide's tolerability profile in trials has been favorable. The combined GLP-1/GIP profile produces the strongest body weight and glycemic results currently approved in the class.
Glucagon Receptor Agonism: The Survodutide Profile
Glucagon receptor agonism acts primarily at the liver and the adipocyte. Glucagon receptor activation drives hepatic fatty acid oxidation and reduces hepatic lipid accumulation through pathways that are distinct from insulin sensitization. The liver is the primary therapeutic target for glucagon receptor agonism in a metabolic context. This is the mechanism behind survodutide's MASH profile.
Practical Treatment Framework
For a patient whose primary concern is body weight reduction with favorable glycemic and cardiometabolic effects, tirzepatide's Phase 3 data and FDA approval make it the current standard. For a patient with obesity plus established MASH or significant hepatic steatosis, survodutide's glucagon receptor component gives it a mechanistic advantage that GLP-1 alone or GLP-1/GIP cannot match with equivalent potency. These are mechanistically differentiated for distinct patient populations, not interchangeable competitors.
The Glycemic Caution
The glucagon receptor component in survodutide raises a theoretical concern about glycemic effects. Glucagon receptor agonism can drive hepatic glucose production, which is counterproductive in patients with poorly controlled type 2 diabetes. The SYNCHRONIZE-2 trial enrolled T2D patients with a mean baseline HbA1c of 7.4%. Phase 3 results will determine whether the GLP-1 offset is clinically sufficient across the full range of baseline glycemic control in the real-world T2D population.
What MASH Is and Why It Is Hard to Treat
Metabolic dysfunction-associated steatohepatitis is the inflammatory, progressive form of hepatic steatosis. It is characterized by hepatocyte ballooning, lobular inflammation, and progressive fibrosis. In its advanced form it progresses to cirrhosis and hepatocellular carcinoma. It affects an estimated 6 to 8% of adults globally. Until resmetirom's approval in March 2024, there was no approved pharmacotherapy beyond lifestyle modification.
Why Fat Accumulates in the Liver
Hepatic steatosis develops when the liver takes in more fatty acids than it can oxidize or export. The three sources of hepatic fatty acids are: free fatty acids released from adipose tissue via lipolysis, de novo lipogenesis from excess carbohydrate intake, and dietary fat delivered via chylomicron remnants. In insulin resistance, all three pathways are dysregulated simultaneously. Lipolysis increases because insulin's normal suppression of adipose lipolysis is impaired. De novo lipogenesis increases because hyperinsulinemia drives SREBP-1c transcription. The liver accumulates fat.
What GLP-1 Agonism Does and Does Not Do for the Liver
GLP-1 receptor agonism addresses hepatic steatosis indirectly. By reducing appetite and caloric intake, GLP-1 agonists reduce the substrate load arriving at the liver. By improving peripheral insulin sensitivity and reducing hyperinsulinemia over time, they reduce the lipogenic stimulus. These are meaningful effects and explain why semaglutide showed MASH benefit in the ESSENCE trial. But GLP-1 receptor expression in the liver itself is low. The GLP-1 receptor effects on hepatic metabolism are largely indirect, mediated through reduced substrate delivery and improved systemic insulin sensitivity rather than direct hepatocyte signaling.
What Glucagon Receptor Agonism Adds
Glucagon receptor expression in the liver is high. Glucagon directly activates hepatic fatty acid oxidation via cyclic AMP and protein kinase A signaling. It increases the expression of genes involved in mitochondrial beta-oxidation, the process by which hepatocytes burn fatty acids for energy rather than storing them as triglycerides. In the context of a dual agonist like survodutide, glucagon receptor activation provides a direct hepatocyte-level stimulus for fat oxidation that GLP-1 receptor agonism cannot replicate with equivalent potency.
Why Pure Glucagon Receptor Agonism Does Not Work
The combination of GLP-1 and glucagon in a single molecule requires careful dose balancing. Pure glucagon receptor agonism drives hepatic glucose production and causes hyperglycemia. Survodutide's GLP-1 component provides the insulin secretion stimulus that offsets this effect, maintaining glycemic control while allowing the glucagon component to drive hepatic fat oxidation. This pharmacological balance is the core design rationale behind survodutide and is why the glucagon receptor alone was never a viable therapeutic target in metabolic disease.
Broader Implications for the Compound Database
The glucagon receptor is the mechanism behind the liver-specific profiles of survodutide, mazdutide, and the next-generation triple agonist candidates being developed beyond retatrutide. Understanding this receptor is the prerequisite for understanding the next five years of metabolic medicine development. Every compound in the database that claims liver-specific metabolic benefit should be evaluated for whether it activates the glucagon receptor directly or relies on the indirect GLP-1 pathway.
The Complete April 15 List: All Twelve Compounds
Issue 2 covered the seven peptides announced for FDA Pharmacy Compounding Advisory Committee review at the July 23 and 24 meetings: BPC-157, KPV, TB-500, MOTS-c, Emideltide (DSIP), Semax, and Epithalon. The April 15 announcement from HHS Secretary Kennedy actually covered twelve compounds. Five were not covered in most reporting.
The five additional compounds are LL-37, DiHexa, GHK-Cu (injectable form only), PEG-MGF, and Melanotan II.
LL-37
LL-37 is the only human cathelicidin, an endogenous antimicrobial peptide with genuine wound care and anti-infective applications. It has been under Category 2 restriction alongside the other compounds despite a reasonable safety profile and a mechanism that is entirely distinct from the immunomodulatory and performance compounds that triggered the original Category 2 concerns. Its inclusion in the reconsideration process is one of the more straightforward cases on the list.
DiHexa
DiHexa was placed in Category 2 at a time when the foundational research from Athira Pharma was already under scrutiny for research integrity issues. The LIFT-AD Phase 2/3 Alzheimer's trial subsequently failed all primary and key secondary endpoints in 2024. Athira paid over $4 million in False Claims Act settlements in 2025. DiHexa's inclusion in a regulatory reconsideration process requires the advisory committee to evaluate whether the compound's evidence base justifies the exercise.
GHK-Cu Injectable
The injectable form is the formulation at issue, not the topical cosmetic form, which has been commercially available without restriction. The injectable form has been Category 2 since 2023. The topical form, which has genuine RCT data behind it including a 2023 split-face trial showing 22% skin firmness improvement, is unaffected by either the original restriction or the current reconsideration. Non-injectable GHK-Cu has been separately noted for further consideration by February 2027.
PEG-MGF and Melanotan II
PEG-MGF is a PEGylated form of mechano growth factor, a splice variant of IGF-1. Its Category 2 status reflected concerns about misuse in athletic performance contexts. The compound has no approved clinical indication and limited published human data. Melanotan II has no regulatory approval anywhere and multiple published case reports of melanoma diagnosis following use in the dermatology literature. Its inclusion alongside compounds with legitimate clinical development histories is the most surprising element of the complete list.
The Same Caveats Apply to All Twelve
Advisory committee review is not approval. Committee recommendations are non-binding. FDA final determinations typically take 6 to 12 months after committee meetings. Nothing in the April 15 announcement changes the current compounding status for any of these compounds. The docket for public comment is FDA-2025-N-6895. Comments must be submitted before July 9, 2026 to be provided to the committee.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use